ABSTRACT
Autologous hematopoietic stem cell (HSC) transplant regimens for autoimmune disease may be roughly separated into myeloablative or nonmyeloablative regimens. Myeloablative regimens were borrowed from regimens designed for cancer and HSCs must be reinfused for safe hematopoietic recovery. Nonmyeloablative regimens were designed for autoimmune diseases, and while HSC reinfusion hastens engraftment, HSCs are not necessary for safe recovery. This chapter discusses the rationale for these separate approaches and the toxicity of drugs in condition regimens used for autoimmune diseases.
